Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study

Table 2 Cumulative cases and deaths of 9-valent HPV-related diseases in the Japanese population prevented, by strategy

Strategy	Anal Cancer		Oropharyngeal Cancer		Penile Cancer	Vaginal Cancer	Vulvar Cancer	JORRP
	Male	Female	Male	Female	Male	Female	Female	Male	Female
Cases
4vHPV	5664	7775	11,414	5392	235	3152	1807	4587	3193
9vHPV	6147	8355	11,784	5618	411	4264	2323	4587	3193
9vHPV + Catch Up	7105	9541	13,824	6455	470	4856	2669	4875	3393
Deaths
4vHPV	778	960	4114	1760	42	897	290	206	143
9vHPV	845	1032	4247	1834	70	1220	377	206	143
9vHPV + Catch Up	983	1186	5041	2137	81	1412	441	220	153

Girls-only vaccination with 4vHPV included routine vaccination of 12–16-year old girls with 4vHPV from 2021 onwards; Girls-only vaccination with 9vHPV included routine vaccination of 12–16-year old girls with 9vHPV; Girls-only routine and catch-up vaccination with 9vHPV consisted of routine vaccination of 12–16-year old girls from 2021 onwards and temporary catch-up vaccination of 17–26 years old girls and women with 9vHPV until 2025. All vaccination strategies were combined with cervical cancer screening

ISSN: 1471-2334